| meta-analysis | Q815382 |
| systematic review | Q1504425 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Gennaro Giustino | Q41445744 |
| Roxana Mehran | Q43249705 | ||
| Samantha Sartori | Q59289119 | ||
| George D Dangas | Q63256402 | ||
| Ioannis Mastoris | Q87491523 | ||
| Annapoorna S Kini | Q88552667 | ||
| Samin K Sharma | Q89840317 | ||
| Usman Baber | Q114304186 | ||
| P2093 | author name string | Stuart J. Pocock | |
| P2860 | cites work | Meta-analysis in clinical trials | Q27860779 |
| Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses | Q27860840 | ||
| Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents | Q28174787 | ||
| Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment | Q28219004 | ||
| Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization | Q28222382 | ||
| Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials | Q34021163 | ||
| Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomize | Q34207990 | ||
| 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q34231154 | ||
| Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis | Q35283386 | ||
| Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents | Q35783487 | ||
| Clinical end points in coronary stent trials: a case for standardized definitions | Q36807166 | ||
| Stent thrombosis | Q37800221 | ||
| Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium | Q37889006 | ||
| Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials | Q38054689 | ||
| ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting | Q38417372 | ||
| Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial | Q38443515 | ||
| Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). | Q38457712 | ||
| Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial | Q38474249 | ||
| Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study | Q38479317 | ||
| Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry | Q39986890 | ||
| A prospective natural-history study of coronary atherosclerosis | Q41983924 | ||
| Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type | Q47750245 | ||
| Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. | Q51067690 | ||
| Short versus long duration of DAPT after DES implantation: a meta-analysis. | Q51796431 | ||
| Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. | Q52643133 | ||
| Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatmen | Q53103119 | ||
| 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu | Q53460540 | ||
| A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) | Q85015607 | ||
| Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial | Q85337405 | ||
| 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial | Q86150404 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| systematic review | Q1504425 | ||
| P304 | page(s) | 1298-310 | |
| P577 | publication date | 2015-04-07 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials | |
| P478 | volume | 65 |
| Q64239348 | "No Such Thing as a Free Lunch": Personalized P2Y Inhibition to Optimize Patient Outcomes |
| Q57621041 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS |
| Q50089557 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. |
| Q53078833 | 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. |
| Q38918975 | A risk scoring system to predict coronary stent thrombosis |
| Q47657861 | Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications |
| Q52593614 | Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. |
| Q28072522 | Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation |
| Q50950524 | Assessing the optimal strategy for dual antiplatelet therapy. |
| Q36996193 | Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys |
| Q36573521 | Causes of late mortality with dual antiplatelet therapy after coronary stents |
| Q93092257 | Comparison of ACUITY, CRUSADE, and GRACE Risk Scales for Predicting Clinical Outcomes in Patients Treated with Dual-Antiplatelet Therapy |
| Q58614119 | Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction |
| Q38591868 | Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal? |
| Q48165705 | Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome |
| Q38578616 | Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents |
| Q38708145 | Developing drugs for use before, during and soon after percutaneous coronary intervention. |
| Q64935943 | Diabetes and antiplatelet therapy: from bench to bedside. |
| Q38548210 | Drug eluting stents versus bare metal stents for the treatment of extracranial vertebral artery disease: a meta-analysis |
| Q53200993 | Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Which Regimen and for How Long? |
| Q38692636 | Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease |
| Q38866836 | Dual antiplatelet therapy after coronary stenting |
| Q39129014 | Dual antiplatelet therapy and non-cardiac surgery: evolving issues and anesthetic implications |
| Q41111747 | Dual antiplatelet therapy duration after drug-eluting stents: how long? |
| Q85362480 | Dual antiplatelet therapy duration and mortality - Authors' reply |
| Q53506248 | Dual antiplatelet therapy following drug-eluting stent implantation: how long is long enough? |
| Q42650020 | Dual antiplatelet therapy for secondary prevention of coronary artery disease. |
| Q26799079 | Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence |
| Q90213322 | Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis |
| Q41960465 | Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. |
| Q39338217 | Duration of dual antiplatelet therapy following drug-eluting stent implantation: A systemic review and meta-analysis of randomized controlled trials with longer follow up. |
| Q33642986 | Duration of dual antiplatelet therapy in patients treated with percutaneous coronary intervention for coronary chronic total occlusion. |
| Q90074563 | Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q28552288 | Early Clinical Experience with a Polymer-Free Biolimus A9 Drug-Coated Stent in DES-Type Patients Who Are Poor Candidates for Prolonged Dual Anti-Platelet Therapy |
| Q40364494 | Early healing assessment with optical coherence tomography of everolimus-eluting stents with bioabsorbable polymer (synergy™) at 3 and 6 months after implantation |
| Q50216134 | Early vascular responses after everolimus-eluting stent implantation assessed by serial observations of intracoronary optical coherence tomography |
| Q93011947 | Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial |
| Q89976942 | Efficacy and Safety of Long-Term and Short-Term Dual Antiplatelet Therapy: A Meta-Analysis of Comparison between Asians and Non-Asians |
| Q36237726 | Efficacy and Safety of Novel Oral P2Y12 Receptor Inhibitors in Patients With ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Systematic Review and Meta-Analysis. |
| Q55282779 | Efficacy and safety of short-term (≤6 months) duration of dual antiplatelet therapy after drug-eluting stents: a meta-analysis of randomized controlled trials. |
| Q55482186 | Evaluation of the Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Bleeding Score for Predicting the Long-term Out-of-hospital Bleeding Risk in Chinese Patients after Percutaneous Coronary Intervention. |
| Q47654430 | Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients. |
| Q48186650 | Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease. |
| Q89252127 | Lights and shadows of long-term dual antiplatelet therapy in "real life" clinical scenarios |
| Q36081846 | Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting. |
| Q38704416 | Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration |
| Q38577755 | Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials |
| Q44888352 | Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting |
| Q30248679 | Long-term use of dual antiplatelet therapy for the secondary prevention of atherothrombotic events: Meta-analysis of randomized controlled trials |
| Q51660216 | Mortality risk with dual antiplatelet therapy? |
| Q45196015 | Mortality risk with dual antiplatelet therapy? - Authors' reply |
| Q49088428 | One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper |
| Q38526074 | Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials |
| Q92099516 | Optimal duration for dual antiplatelet therapy with COMBO dual therapy stent |
| Q59811532 | Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome |
| Q47136631 | Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis. |
| Q38706266 | Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence |
| Q55311019 | Optimal duration of dual antiplatelet therapy for coronary artery disease. |
| Q38561878 | Oral dual antiplatelet therapy: what have we learnt from recent trials? |
| Q30239889 | Outcomes of ≤6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation: A meta-analysis and meta-regression |
| Q38728869 | Percutaneous Coronary Intervention: 2015 in Review |
| Q57154436 | Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations |
| Q90288915 | Predictors of stent thrombosis and their implications for clinical practice |
| Q44418463 | Prolonged antiplatelet therapy after drug-eluting stents |
| Q55040250 | Propylthiouracil-coated biodegradable polymer inhibited neointimal formation and enhanced re-endothelialization after vascular injury. |
| Q92929839 | Pros and Cons of Aspirin Prophylaxis for Prevention of Cardiovascular Events in Kidney Transplantation and Review of Evidence |
| Q36624476 | Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials |
| Q51739975 | Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials. |
| Q42125281 | Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: A comparison between the DAPT study and 9 other trials evaluating DAPT duration |
| Q39592831 | Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials |
| Q36117653 | Should a prolonged duration of dual anti-platelet therapy be recommended to patients with diabetes mellitus following percutaneous coronary intervention? A systematic review and meta-analysis of 15 studies |
| Q38970275 | Single or dual antiplatelet therapy after PCI. |
| Q57044145 | Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial |
| Q50997272 | Smart Microbubble Eluting Theranostic Stent for Noninvasive Ultrasound Imaging and Prevention of Restenosis. |
| Q38579536 | Stable coronary artery disease: revascularisation and invasive strategies |
| Q41607661 | Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice |
| Q41367415 | Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial |
| Q38685684 | The year in cardiology 2015: coronary intervention |
| Q41767985 | Time for science to catch up with clinical practice? |
| Q90647716 | Two common mutations within CYP2C19 affected platelet aggregation in Chinese patients undergoing PCI: a one-year follow-up study |
| Q90529438 | Update on Antithrombotic Therapy after Percutaneous Coronary Intervention |
| Q38556885 | Update on antithrombotic therapy after percutaneous coronary revascularisation |
| Q38813540 | What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation? |
Search more.